Safety of the newer class of opioid antagonists in pregnancy;Sécurité de la plus récente classe d'antagonistes des opioïdes durant la grossesse

Canadian Family Physician

Volumn 60, Issue 7, 2014, Pages

  Poon, Shirley ^a   Pupco, Anna ^a   Koren, Gideon ^a   Bozzo, Pina ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; NALOXONE; OPIATE ANTAGONIST; DRUG COMBINATION; NARCOTIC ANTAGONIST;

ADVERSE OUTCOME; DRUG SAFETY; DRUG USE; HUMAN; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; REVIEW; CONTRAINDICATIONS; DRUG COMBINATION; FEMALE; OPIOID-RELATED DISORDERS; PREGNANCY COMPLICATIONS;

BUPRENORPHINE; DRUG COMBINATIONS; FEMALE; HUMANS; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84904392733     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Kuczkowski KM. The effects of drug abuse on pregnancy. Curr Opin Obstet Gynecol 2007;19(6):578-85. (Pubitemid 350135442)
2. Heil SH, Jones HE, Arria A, Kaltenbach K, Coyle M, Fischer G et coll. Unintended pregnancy in opioid-abusing women. J Subst Abuse Treat 2011;40(2):199-202. Cyberpub. du 30 octobre 2010.
3. Treatment Episode Data Set (TEDS): 1997-2007. National admissions to substance abuse treatment services. DASIS Series: S-47, DHHS Publication No. (SMA) 09-4379. Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies; 2009. Accessible à: http://samhsa.gov/data/DASIS/TEDS2k7AWeb/TEDS-2k7AWeb.pdf. Réf. du 19 aoÛt 2013.
4. Dashe JS, Jackson GL, Olscher DA, Zane EH, Wendel GD Jr. Opioid detoxification in pregnancy. Obstet Gynecol 1998;92(5):854-8. (Pubitemid 28487688)
5. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstet Gynecol Clin North Am 1998;25(1):139-51. (Pubitemid 28141705)
6. Wong S, Ordean A, Kahan M; Société des obstétriciens et gynécologues du Canada. SOGC clinical practice guidelines: substance use in pregnancy: no 256, avril 2011. Int J Gynaecol Obstet 2011;114(2):190-202.
7. Johnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend 2003;70(2 Suppl):S87-101.
8. Jones HE, Heil SH, Baewert A, Arria AM, Kaltenbach K, Martin PR et coll. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction 2012;107(Suppl 1):5-27.
9. Pritham UA, Paul JA, Hayes MJ. Opioid dependency in pregnancy and length of stay for neonatal abstinence syndrome. J Obstet Gynecol Neonatal Nurs 2012;41(2):180-90. Cyberpub. du 29 février 2012.
10. Welle-Strand GK, Skurtveit S, Jones HE, Waal H, Bakstad B, Bjarkø L et coll. Neonatal outcomes following in utero exposure to methadone or buprenorphine: a national cohort study of opioid-agonist treatment of pregnant women in Norway from 1996 to 2009. Drug Alcohol Depend 2013;127(1-3):200-6.
11. Salo S, Kivistö K, Korja R, Biringen Z, Tupola S, Kahila H et coll. Emotional availability, parental self-efficacy beliefs, and child development in caregiver-child relationships with buprenorphine-exposed 3-year-olds. Parent Sci Pract 2009;9(3-4):244-59.
12. Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM et coll. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010;363(24):2320-31.
13. Geber WF, Schramm LC. Congenital malformations of the central nervous system produced by narcotic analgesics in the hamster. Am J Obstet Gynecol 1975;123(7):705-13.
14. Jurand A. The interference of naloxone hydrochloride in the teratogenic activity of opiates. Teratology 1985;31(2):235-40. (Pubitemid 15103549)
15. Suboxone. Highlights of prescribing information [monographie du produit]. Richmond, VA: Reckitt Benckiser Pharmaceuticals; 2014.
16. Debelak K, Morrone WR, O'Grady KE, Jones HE. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy - initial patient care and outcome data. Am J Addict 2013;22(3):252-4.
17. Lund IO, Fischer G, Welle-Strand GK, O'Grady KE, Debelak K, Morrone WR et coll. A comparison of buprenorphine + naloxone to buprenorphine and methadone in the treatment of opioid dependence during pregnancy: maternal and neonatal outcomes. Subst Abuse 2013;7:61-74. Cyberpub. du 14 mars 2013.
18. ACOG Committee on Health Care for Underserved Women; American Society of Addiction Medicine. ACOG Committee Opinion No. 524: opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol 2012;119(5):1070-6.